US FDA’s Genetic Metabolic Diseases Adcomm Debuts With Zevra’s Arimoclomol

 
• By Sue Sutter
  
Stage
The Genetic Metabolic Diseases Adcomm is scheduled for its first meeting on 2 August, although the committee's standing members have not yet been announced. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers